glp-1 obesity drug news today oct 2025 Outlook for in 2025: more than a transition year 2024 was a record year

[DOI] [PMC free article] [PubMed] [Google Scholar] 48.Davies MJ, Bain SC, Atkin SL, et al

Switching to retatrutide from tirzepatide This switch will become relevant as retatrutide moves toward potential approval

Women who are experiencing patterned thinning, distinct from diffuse shedding, during GLP-1 therapy should discuss this hormonal mechanism with their dermatologist

To each tube 0.6 TIU/mL aprotinin was added immediately

95% confidence interval [CI], 3.69 to 2.30) [32]

Stopping GLP-1 medications typically leads to weight regain, with most people regaining 50-70% of lost weight within 12 months as appetite and metabolic adaptations return